Home Compliance Regeneron Case Likely to Join Teva Pharmaceuticals’ FCA Causation Appeal ComplianceExpert OpinionFCA Regeneron Case Likely to Join Teva Pharmaceuticals’ FCA Causation Appeal October 30, 2023 16 Share FacebookLinkedinTwitter Billion Photos | Shutterstock You must be a Paid or Free Trial Member to Access this Content. Paid members, please login to view your news subscription(s). RELATED ARTICLESMORE FROM AUTHOR Compliance Another One Bites the Dust: Incomplete Joint Venture Agreement Fails Once Again Compliance Sovereign and Derivative Immunity in Government Contracts Compliance California Supreme Court Holds Wage Statement Penalties Are Not Available if an Employer Acted in Good Faith